SELLAS Life Sciences Group Inc Dossier - Source-backed chat

SELLAS Life Sciences Group Inc

SLSNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.98

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $11.33Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $2.3B

Enterprise Value $2.1B

Shares Outstanding 196.7M diluted

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company approaching a critical binary inflection point with its Phase 3 REGAL trial evaluating galinpepimut-S (GPS) in acute myeloid leukemia (AML) patients in second complete remission (CR2). As of May 11, 2026, the trial has recorded 78 of the required 80 events to trigger final analysis. While the prolonged trial duration suggests potentially longer-than-expected patient survival (a bullish signal), the stock remains highly speculative and subject to binary clinical trial risk. Additionally, the company is advancing SLS009, a selective CDK9 inhibitor, into frontline AML with topline Phase 2 data expected in Q4 2026. A 'Hold' rating is maintained pending the imminent REGAL unblinding and the HKIAC arbitration ruling against 3D Medicines.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$30.00

Mean target$32.50

High · most bullish analyst$35.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The REGAL trial fails to meet its primary endpoint of overall survival, showing no statistically significant difference between the GPS and BAT arms. This failure invalidates the lead asset's commercial viability in AML CR2, causing a severe decline in share price. The company becomes entirely reliant on SLS009, forcing heavy dilution under its newly filed $154.6 million shelf registration to fund ongoing operations.

Base CaseCentral scenario

The Phase 3 REGAL trial reaches its 80th event in mid-2026, leading to database lock and unblinding. Topline results demonstrate a statistically significant overall survival benefit for GPS compared to best available therapy (BAT), aligning with historical Phase 2 data (median OS of 21 months vs. 5.4 months for BAT). This success paves the way for a Biologics License Application (BLA) filing with the FDA. SLS009 continues to show strong efficacy in high-risk AML subgroups, supporting its development path.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Imminent high-impact catalyst with the Phase 3 REGAL trial final analysis triggered at the 80th event (78 events recorded as of May 11, 2026).
Prolonged trial duration suggests overall survival in the trial population is tracking longer than historical benchmarks, potentially indicating a strong GPS treatment effect.
Differentiated pipeline with SLS009, a selective CDK9 inhibitor showing high response rates in high-risk AML mutations (ASXL1, TP53).
Strengthened capital position with $107.1 million in cash as of March 31, 2026, plus subsequent warrant exercise proceeds.

Key Investment Risks

High binary clinical trial risk associated with the upcoming REGAL unblinding.
Potential for substantial shareholder dilution following the filing of a $154.6 million shelf registration.
Uncertainty surrounding the HKIAC arbitration outcome with Chinese partner 3D Medicines over disputed milestone payments.

Thesis Invalidation Triggers

Failure of the Phase 3 REGAL trial to meet its primary overall survival endpoint.
An adverse ruling in the HKIAC arbitration resulting in the loss of the disputed ~$13 million milestone payments.
Severe safety signals or lack of efficacy in the SLS009 Phase 2 frontline AML trial.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.